News Theramex's uterine fibroid drug Yselty backed for NHS use A daily oral therapy for uterine fibroids has been recommended for NHS by NICE, providing a new option for around 30,000 women in England and Wales.
News ObsEva files uterine fibroid drug in US, chasing AbbVie, Myo... Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number of women eligible for this type of
News Novartis snaps up PI3Kα breast cancer drug in $3bn deal Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.